Literature DB >> 6791048

Pharmacology of valproic acid in children with severe epilepsy: clearance and hepatotoxicity.

W E Dodson, V Tasch.   

Abstract

Valproic acid concentrations correlate with dose in children when sampling times are consistent. Both interpatient variability and average clearance of valproic acid are inversely related to age. Young children usually need higher doses to achieve the same blood levels as other patients, but the levels that result from a dose are less predictable from one child to the next. Whereas valproic acid therapy had little effect on the serum glutamic oxaloacetic transaminase (SGOT), 12% of patients had abnormal SGOTs during an average of 14 months' therapy. The abnormal SGOTs from patients without serious hepatic dysfunction overlap many of the abnormal values in cases of fatal hepatic failure associated with valproic acid.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6791048     DOI: 10.1212/wnl.31.8.1047

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Hepatotoxicity to sodium valproate: a review.

Authors:  P R Powell-Jackson; J M Tredger; R Williams
Journal:  Gut       Date:  1984-06       Impact factor: 23.059

Review 2.  Valproate-induced hyperammonemic encephalopathy.

Authors:  Alberto Verrotti; Daniela Trotta; Guido Morgese; Francesco Chiarelli
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

3.  Rectal administration of sodium valproate in children.

Authors:  E Scanabissi; D Dal Pozzo; E Franzoni; C Galloni; G Mengoli; R Calivà
Journal:  Ital J Neurol Sci       Date:  1984-06

4.  First-dose and steady-state pharmacokinetics of valproic acid in children with seizures.

Authors:  K Hall; N Otten; J Irvine-Meek; M Leroux; D Budnick; M Verma; S S Seshia
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.